[go: up one dir, main page]

WO1998001159A3 - Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires - Google Patents

Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires Download PDF

Info

Publication number
WO1998001159A3
WO1998001159A3 PCT/GB1997/001852 GB9701852W WO9801159A3 WO 1998001159 A3 WO1998001159 A3 WO 1998001159A3 GB 9701852 W GB9701852 W GB 9701852W WO 9801159 A3 WO9801159 A3 WO 9801159A3
Authority
WO
WIPO (PCT)
Prior art keywords
composition
mucosal surfaces
enhanced uptake
polar drugs
metabolisable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1997/001852
Other languages
English (en)
Other versions
WO1998001159A2 (fr
Inventor
Lisbeth Illum
Peter James Watts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyowa Kirin Services Ltd
Original Assignee
Danbiosyst UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Danbiosyst UK Ltd filed Critical Danbiosyst UK Ltd
Priority to EP97930663A priority Critical patent/EP0993305A2/fr
Priority to JP10504949A priority patent/JP2000515503A/ja
Priority to GB9900050A priority patent/GB2330533B/en
Priority to AU34539/97A priority patent/AU722724B2/en
Publication of WO1998001159A2 publication Critical patent/WO1998001159A2/fr
Publication of WO1998001159A3 publication Critical patent/WO1998001159A3/fr
Priority to NO985956A priority patent/NO985956L/no
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Botany (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

L'invention concerne une composition à administrer sur la muqueuse d'un mammifère, comprenant un analogue de sel biliaire non métabolisable et un agent thérapeutique. L'analogue de sel biliaire non métabolisable est de préférence un conjugué d'origine artificielle d'acide cholique et d'un acide aminé, en particulier de la cholysarcosine. L'agent thérapeutique est de préférence une molécule polaire.
PCT/GB1997/001852 1996-07-06 1997-07-07 Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires Ceased WO1998001159A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
EP97930663A EP0993305A2 (fr) 1996-07-06 1997-07-07 Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires
JP10504949A JP2000515503A (ja) 1996-07-06 1997-07-07 極性薬剤の粘膜表面からの摂取を増進するための組成物
GB9900050A GB2330533B (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
AU34539/97A AU722724B2 (en) 1996-07-06 1997-07-07 Composition for enhanced uptake of polar drugs from mucosal surfaces
NO985956A NO985956L (no) 1996-07-06 1998-12-18 Blanding for forbedret opptak av polare medikamenter fra mukosale overflater

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9614235.1 1996-07-06
GBGB9614235.1A GB9614235D0 (en) 1996-07-06 1996-07-06 Composition for enhanced uptake of polar drugs from mucosal surfaces

Publications (2)

Publication Number Publication Date
WO1998001159A2 WO1998001159A2 (fr) 1998-01-15
WO1998001159A3 true WO1998001159A3 (fr) 1998-03-26

Family

ID=10796483

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1997/001852 Ceased WO1998001159A2 (fr) 1996-07-06 1997-07-07 Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires

Country Status (8)

Country Link
EP (1) EP0993305A2 (fr)
JP (1) JP2000515503A (fr)
KR (1) KR20000023583A (fr)
AU (1) AU722724B2 (fr)
CA (1) CA2257563A1 (fr)
GB (2) GB9614235D0 (fr)
NO (1) NO985956L (fr)
WO (1) WO1998001159A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6572874B1 (en) * 1998-05-15 2003-06-03 Umd, Inc. Vaginal delivery of bisphosphonates
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
EP1154761B1 (fr) * 1999-02-22 2008-02-20 Merrion Research I Limited Dose orale solide contenant un agent de potentialisation
GB2355009A (en) 1999-07-30 2001-04-11 Univ Glasgow Peptides conjugated to bile acids/salts
US7053076B2 (en) 2001-08-29 2006-05-30 Xenoport, Inc. Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs
KR100564021B1 (ko) * 2002-12-11 2006-03-24 주식회사종근당 극성 약물의 경구용 약제학적 조성물
DE102004027924A1 (de) * 2004-06-09 2005-12-29 Röhm GmbH & Co. KG Arzneiform, enthaltend den Wirkstoff Cholylsarcosin
ES2426445T3 (es) 2006-04-07 2013-10-23 Merrion Research Iii Limited Forma de dosificación oral sólida que contiene un potenciador
CN107096012A (zh) 2008-05-07 2017-08-29 诺和诺德股份有限公司 肽的组合物及其制备方法
BRPI1015046A2 (pt) 2009-06-18 2016-04-12 Allergan Inc administração segura de desmopressina
WO2011120033A1 (fr) 2010-03-26 2011-09-29 Merrion Research Iii Limited Compositions pharmaceutiques d'inhibiteurs de facteur xa sélectifs destinées à une administration orale
EP2661273A4 (fr) 2011-01-07 2014-06-04 Merrion Res Iii Ltd Compositions pharmaceutiques de fer pour administration orale
US10265384B2 (en) 2015-01-29 2019-04-23 Novo Nordisk A/S Tablets comprising GLP-1 agonist and enteric coating
CN108201531A (zh) * 2016-12-19 2018-06-26 湖南尔康湘药制药有限公司 高溶解性磺苄西林钠结肠靶向淀粉胶囊及其制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (fr) * 1989-01-19 1990-07-26 California Biotechnology Inc. Compositions d'aministration de medicaments a travers des membranes
DE4222647A1 (de) * 1991-07-15 1993-01-21 Sandoz Ag Peptid-zubereitungen
WO1995001183A1 (fr) * 1993-06-29 1995-01-12 Ferring B.V. Compositions permettant l'administration par voie nasale de desmopressine
WO1997006813A1 (fr) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Preparation pour muqueuses a base de peptides a activite physiologique

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007923A1 (fr) * 1989-01-19 1990-07-26 California Biotechnology Inc. Compositions d'aministration de medicaments a travers des membranes
DE4222647A1 (de) * 1991-07-15 1993-01-21 Sandoz Ag Peptid-zubereitungen
WO1995001183A1 (fr) * 1993-06-29 1995-01-12 Ferring B.V. Compositions permettant l'administration par voie nasale de desmopressine
WO1997006813A1 (fr) * 1995-08-15 1997-02-27 Asahi Kasei Kogyo Kabushiki Kaisha Preparation pour muqueuses a base de peptides a activite physiologique

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
AUNGST, BRUCE J. ET AL: "Comparison of nasal, rectal, buccal, sublingual and intramuscular insulin efficacy and the effects of a bile salt absorption promoter", J. PHARMACOL. EXP. THER. (1988), 244(1), 23-8 CODEN: JPETAB;ISSN: 0022-3565, 1988, XP002049338 *
BIOCHEM. PHARMACOL. (1983), 32(5), 773-6 CODEN: BCPCA6;ISSN: 0006-2952, 1983 *
CHEMICAL ABSTRACTS, vol. 112, no. 6, 5 February 1990, Columbus, Ohio, US; abstract no. 42406, NAGAI, T. ET AL: "Absorption of fibroblast interferon -.beta. in powder dosage form from nasal mucosa in rabbits" XP002049341 *
CHEMICAL ABSTRACTS, vol. 95, no. 13, 28 September 1981, Columbus, Ohio, US; abstract no. 109081, ZIV, EHUD ET AL: "Bile salts promote the absorption of insulin from the rat colon" XP002049343 *
CHEMICAL ABSTRACTS, vol. 98, no. 23, 6 June 1983, Columbus, Ohio, US; abstract no. 191258, ZIV, E. ET AL: "Bile salts facilitate the absorption of heparin from the intestine" XP002049342 *
CONGR. INT. TECHNOL. PHARM., 5TH (1989), VOLUME 1, 91-8 PUBLISHER: ASSOC. PHARM. GALENIQUE IND., CHATENAY MALABRY, FR. CODEN: 56SEA5, 1989 *
GORDON, G. S. ET AL: "Nasal absorption of insulin: enhancement by hydrophobic bile salts", PROC. NATL. ACAD. SCI. U. S. A. (1985), 82(21), 7419-23 CODEN: PNASA6;ISSN: 0027-8424, 1985, XP002049334 *
KRAMER W ET AL: "MODIFIED BILE ACIDS AS CARRIERS FOR PEPTIDES AND DRUGS", JOURNAL OF CONTROLLED RELEASE, vol. 46, no. 1/02, 5 May 1997 (1997-05-05), pages 17 - 30, XP000680749 *
LIFE SCI. (1981), 29(8), 803-9 CODEN: LIFSAK;ISSN: 0024-3205, 1981 *
LONGENECKER, JOHN P. ET AL: "Effects of sodium taurodihydrofusidate on nasal absorption of insulin in sheep", J. PHARM. SCI. (1987), 76(5), 351-5 CODEN: JPMSAE;ISSN: 0022-3549, 1987, XP002049340 *
NAKADA, YUICHIRO ET AL: "The effect of additives on the oral mucosal absorption of human calcitonin in rats", J. PHARMACOBIO-DYN. (1988), 11(6), 395-401 CODEN: JOPHDQ;ISSN: 0386-846X, 1988, XP002049337 *
NAKADA, YUICHIRO ET AL: "The effect of bile salts on the oral mucosal absorption of human calcitonin in rats", J. PHARMACOBIO-DYN. (1989), 12(12), 736-43 CODEN: JOPHDQ;ISSN: 0386-846X, 1989, XP002049336 *
SCOTT-MONCRIEFF, J. CATHARINE ET AL: "Enhancement of Intestinal Insulin Absorption by Bile Salt Fatty Acid Mixed Micelles in Dogs", J. PHARM. SCI. (1994), 83(10), 1465-9 CODEN: JPMSAE;ISSN: 0022-3549, 1994, XP002049335 *
UCHIDA, NAOKI ET AL: "Influence of bile salts on the permeability of insulin through the nasal mucosa of rabbits in comparison with dextran derivatives", INT. J. PHARM. (1991), 74(2-3), 95-103 CODEN: IJPHDE;ISSN: 0378-5173, 1991, XP002049339 *

Also Published As

Publication number Publication date
EP0993305A2 (fr) 2000-04-19
NO985956D0 (no) 1998-12-18
NO985956L (no) 1998-12-18
AU3453997A (en) 1998-02-02
JP2000515503A (ja) 2000-11-21
WO1998001159A2 (fr) 1998-01-15
GB2330533A (en) 1999-04-28
GB9614235D0 (en) 1996-09-04
GB2330533B (en) 2000-10-25
CA2257563A1 (fr) 1998-01-15
AU722724B2 (en) 2000-08-10
GB9900050D0 (en) 1999-02-24
KR20000023583A (ko) 2000-04-25

Similar Documents

Publication Publication Date Title
WO1998001159A3 (fr) Composition en vue d'une meilleure assimilation par les muqueuses de medicaments a molecules polaires
CA2304958A1 (fr) Compositions bioadhesives et methodes d'administration locale d'agents actifs
WO2003079972A3 (fr) Systemes de distribution d'agents actifs et methodes de protection et d'administration d'agents actifs
WO1997044063A3 (fr) Conjugues d'acide cis-docosahexanoïque et d'agents pharmaceutiques
AU6675198A (en) Transdermal drug delivery system for the administration of tamsulosin, and related compositions and methods of use
WO1997049736A3 (fr) Particules comprenant des copolymeres amphiphiles, possedant un domaine de reticulation croisee et un domaine de noyau interne, utilisables en pharmacologie et autres applications
AU4063697A (en) Methods for regulating gastrointestinal motility
WO2000038626A3 (fr) Composition de substrat et procede d'utilisation associe, aux fins de sequestration de substances irritantes pour la peau
WO2000033825A3 (fr) Compositions et methodes visant a attenuer un dysfonctionnement sexuel chez la femme
BG104245A (en) Plasma protein-containing pharmaceutical compositions
ZA964735B (en) Compositions and methods for topical administration of pharmaceutically active agents
AU3435497A (en) Autocross-linked hyaluronic acid and related pharmaceutical compositions for the treatment of arthropathies
EP0354992A3 (fr) Conjugués de VIP et de ses fragments actifs avec des portions hydrophobiques et des préparations pour l'utilisation dans le traitement de l'impuissance masculine
AU2001264515A1 (en) Melphalan derivatives and their use as cancer chemotherapeutic drugs
HUP0302333A3 (en) The use of glatiramer acetate (copolymer 1) for the preparation of pharmaceutical compositions available in the treatment of central nervous system disorders
CA2268455A1 (fr) Methodes et appareil de traitement de la maladie de parkinson
WO2002009679A3 (fr) Utilisation de l'acide 13-cis-retinoique pour le traitement de l'emphyseme
CA2268305A1 (fr) Utilisation d'un inhibiteur de h+, k+-atpase dans le traitement de polypes du nez
AU3771697A (en) Amino acid compositions and use thereof in immunosuppression
WO2002058589A3 (fr) Agents et methodes favorisant la croissance osseuse
RU99103692A (ru) Аминокислотные композиции и их применение при иммунодепрессии
CA2272880A1 (fr) Composition et procede permettant de reduire la sensation d'irritation de la peau
CA2189145A1 (fr) Tri-, tetra-, penta- et polypeptides et leur usage therapeutique en tant qu'agent antidepresseur
WO2001005383A3 (fr) Inhibition de l'absorption renale de molecules pouvant potentiellement endommager les reins
AU2921999A (en) Indole-2,3-dione-3-oxime derivatives for therapeutic use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA GB JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA GB JP KR NO US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2257563

Country of ref document: CA

Ref country code: CA

Ref document number: 2257563

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: GB

Ref document number: 9900050

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1997930663

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 1019997000028

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 09214527

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1997930663

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1019997000028

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1997930663

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1019997000028

Country of ref document: KR